COVID-19 and patients with immune-mediated inflammatory diseases undergoing pharmacological treatments: a rapid living systematic review

Rocha, Aline Pereira da; Atallah, Álvaro Nagib; Pinto, Ana Carolina Pereira Nunes; Rocha-Filho, César Ramos; Milby, Keilla Martins; Civile, Vinicius Tassoni; Carvas, Nelson; Reis, Felipe Sebastião de Assis; Ferla, Laura Jantsch; Ramalho, Gabriel Sodré; Trevisani, Giulia Fernandes Moça; Puga, Maria Eduarda dos Santos; Trevisani, Virgínia Fernandes Moça

doi:10.1590/1516-3180.2020.0421.r2.10092020

Cited by 4 publications

(7 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Most (89.1%) LSRs were published in SCI journal. 16–21 , 23–44 , 46–51 , 53–57 , 59–69 , 73–79 The impact factor published in SCI journals ranged from 1.04 to 39.89, with an average of 11.72 and a standard deviation of 11.30. The impact factor of 64.1% studies was >5, 16–20 , 23 , 26 , 27 , 30 , 32 , 33 , 36 , 37 , 39–44 , 46 , 47 , 49–51 , 54–57 , 60–64 , 67–69 , 73–76 , 79 the impact factor of 17.2% studies was >15.…”

Section: Resultsmentioning

confidence: 99%

“…In the production phase of LSR, most of the LSRs registered [16][17][18][19][20][21][22]25,26,[28][29][30][31][32][33]35,37,[39][40][41][42][45][46][47][48][49][50][51][52][53][54][55][56][57][58][59][60][61][62][65][66][67][69][70][71][72][73][76][77][78][79] (81.2%) and wrote the protocol [16]…”

Section: Methodology Of Lsr For Covid-19mentioning

confidence: 99%

“…Most (89.1%) LSRs were published in SCI journal. [16][17][18][19][20][21][46][47][48][49][50][51][53][54][55][56][57][59][60][61][62][63][64][65][66][67][68][69][73][74][75][76][77][78][79] The impact factor published in SCI journals ranged from 1.04 to 39.89, with an average of 11.72 and a standard deviation of 11.30. The impact factor of 64.1% studies was >5, [16][17][18][19][20]23,26,27,30,32,33,36,37,[39][40][41...…”

Section: Study Selectionmentioning

confidence: 99%

See 2 more Smart Citations

Characteristics of Living Systematic Review for COVID-19

Chen¹,

Luo²,

Li³

et al. 2022

CLEP

View full text Add to dashboard Cite

Purpose The systematic review aims to analyze and summarize the characteristics of living systematic review (LSR) for coronavirus disease 2019 (COVID-19). Methods Six databases including Medline, Excerpta Medica (Embase), Cochrane Library, China National Knowledge Infrastructure (CNKI), Wanfang Database and China Science, and Technology Journal Database (VIP), were searched as the source of basic information and methodology of LSR. Descriptive analytical methods were used to analyze the included COVID-19 LSRs, and the study characteristics of COVID-19 LSRs were further assessed. Results Sixty-four COVID-19 LSRs were included. Eighty-nine point one percent of LSRs were published on Science Citation Index (SCI) journals, and 64.1% publication with an impact factor (IF) >5 and 17.2% with an IF >15 among SCI journals. The first unit of the published LSRs for COVID-19 came from 19 countries, with the largest contribution from the UK (17.2%, 11/64). Forty point six percent of LSRs for COVID-19 were related to therapeutics topic which was considered the most concerned perspective for LSRs for COVID-19. Seventy-six point six percent of LSRs focused on the general population, with less attention to children, pregnant women and the elderly. However, the LSR for COVID-19 was reported incomplete on “living” process, including 40.6% of studies without search frequency, 79.7% of studies without screening frequency, 20.3% of studies without update frequency, and 65.6% of studies without the timing or criteria of transitioning LSR out of living mode. Conclusion Although researchers in many countries have applied LSRs to COVID-19, most of the LSRs for COVID-19 were incomplete in reporting on the “living” process and less focused on special populations. This could reduce the confidence of health-care providers and policy makers in the results of COVID-19 LSR, thereby hindering the translation of evidence on COVID-19 LSR into clinical practice. It was necessary to explicitly enact preferred reporting items for systematic reviews and meta-analyses (PRISMA) to improve the reporting quality of LSR and support ongoing efforts of therapeutics research for special patients with COVID-19.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Methodology Of Lsr For Covid-19mentioning

confidence: 99%

Section: Study Selectionmentioning

confidence: 99%

See 1 more Smart Citation

Characteristics of Living Systematic Review for COVID-19

Chen¹,

Luo²,

Li³

et al. 2022

CLEP

View full text Add to dashboard Cite

show abstract

“…The remission of RA following varicella-zoster infection has been reported in the literature [4]. The temporal relationship between the disappearance of all signs and symptoms of RA within a few days after COVID-19 pneumonia or any viral infection raises the suspicion of a link between the two diseases [2]. Remission after COVID-19 infection is limited to arthritis, but many other chronic conditions also demonstrated significant improvement.…”

Section: Improvement or Complete Remission Of Autoimmune Inflammatory...mentioning

confidence: 94%

“…Our search yielded 2 case series. In one series, patients on immunosuppressive therapy for immune-medicated inflammatory diseases, there was a higher risk of invasive mechanical ventilation [2]. In another retrospective study over 9 months, 25 patients with RA developed COVID-19 with a higher risk of severity [3].…”

Section: Search Strategymentioning

confidence: 99%

Complete persistent remission of rheumatoid arthritis after COVID-19 infection - A rare case and literature review

Barman

Nune

Ish

et al. 2022

Monaldi Arch Chest Dis

View full text Add to dashboard Cite

A 55-year-old man was admitted to a hospital in Northeast India with fever, cough and breathlessness and was diagnosed with severe COVID-19 pneumonia. He was a known case of seropositive, erosive rheumatoid arthritis (RA) and was taking disease-modifying anti-rheumatic drugs (DMARDs). The patient was treated with remdesivir, heparin and a short course of corticosteroids for COVID-19 pneumonia. With the improvement of COVID-19 pneumonia, the patient also noticed a marked improvement in his joint symptoms despite not taking any DMARDs for RA. The temporal relationship between the time of disappearance of all signs and symptoms of RA within a few days after COVID-19 pneumonia and maintenance of RA remission for over one year of follow up to date suggests that COVID-19 likely caused the remission of RA. This case highlights the need for larger studies to understand the COVID-19 effects on RA remission and their potential link if any. However, the evidence of worse outcome with COVID-19 in immunosuppression which is common in RA cannot be overlooked.

show abstract

Clinical characteristics and outcome of COVID-19 in patients with rheumatic diseases

2021

View full text Add to dashboard Cite

This study aimed to assess the baseline characteristics and clinical outcomes of coronavirus disease 2019 (COVID-19) in patients with rheumatic diseases and identify the risk factors associated with severe COVID-19 pneumonia. This was a retrospective study in a tertiary care center conducted through the period between March 2020 and November 2020 and included all adult patients with rheumatic diseases who tested positive on the COVID-19 polymerase chain reaction (PCR) test. We assessed the patients’ demographic data, history of rheumatic disease, COVID-19 symptoms and experimental treatment, if any, their disease course, and outcome. In all, 47 patients were included, and most were females. The commonest rheumatic diseases were rheumatoid arthritis (53.2%), followed by systemic lupus erythematosus (21.3%), and psoriatic arthritis (10.6%). Methotrexate and hydroxychloroquine were the most commonly used disease-modifying anti-rheumatic drugs in 36.1% and 25.5%, respectively. Out of 47 patients, 48.9% required hospitalization with a median hospital stay of 7 days. Severe COVID-19 pneumonia, defined as clinical signs of pneumonia plus one of the following: respiratory rate > 30 bpm, severe respiratory distress, or oxygen saturation < 90% in room air was observed in 19.1% of the patients, and one patient died. We found that elderly patients with a mean age of 65.3 years were more likely to develop severe COVID-19 pneumonia and that was statistically significant. Our study showed that elderly patients with a mean age of 65 years and having rheumatic diseases had an increased risk of hospital admission and development of severe COVID-19 pneumonia.

show abstract

COVID-19 and patients with immune-mediated inflammatory diseases undergoing pharmacological treatments: a rapid living systematic review

Cited by 4 publications

References 29 publications

Characteristics of Living Systematic Review for COVID-19

Characteristics of Living Systematic Review for COVID-19

Complete persistent remission of rheumatoid arthritis after COVID-19 infection - A rare case and literature review

Clinical characteristics and outcome of COVID-19 in patients with rheumatic diseases

Contact Info

Product

Resources

About